8. Bondi SK, Goldberg JB: Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev Vaccines 2008,7(9):1357–1365.PubMedCrossRef 9. Galyov EE, Brett PJ, Deshazer D: Molecular Insights into Burkholderia Ruboxistaurin cost pseudomallei and Burkholderia mallei Pathogenesis. Annu Rev GW786034 mouse Microbiol 2010, 64:495–517.PubMedCrossRef 10. DeShazer D, Brett PJ,

Woods DE: The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 1998,30(5):1081–1100.PubMedCrossRef learn more 11. Egan AM, Gordon DL:

Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect Immun 1996,64(12):4952–4959.PubMed 12. Reckseidler-Zenteno SL, DeVinney R, Woods DE: The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun 2005,73(2):1106–1115.PubMedCrossRef 13. Jones AL, DeShazer D, Woods DE: Identification and characterization of a two-component regulatory system involved in invasion of eukaryotic cells and heavy-metal resistance in Burkholderia pseudomallei. Infect Immun 1997,65(12):4972–4977.PubMed 14. Jones AL, Beveridge TJ, Woods DE: Intracellular survival of Burkholderia pseudomallei.

Infect Immun 1996,64(3):782–790.PubMed 15. Burtnick MN, Woods DE: Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance. Antimicrob Agents Chemother 1999,43(11):2648–2656.PubMed 16. Stevens JM, Ulrich RL, Taylor LA, Wood MW, Deshazer D, Stevens MP, Galyov EE: Actin-binding proteins from Burkholderia mallei and Burkholderia thailandensis can functionally compensate for the actin-based motility Arachidonate 15-lipoxygenase defect of a Burkholderia pseudomallei bimA mutant. J Bacteriol 2005,187(22):7857–7862.PubMedCrossRef 17. Stevens MP, Stevens JM, Jeng RL, Taylor LA, Wood MW, Hawes P, Monaghan P, Welch MD, Galyov EE: Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei. Mol Microbiol 2005,56(1):40–53.PubMedCrossRef 18. Stevens MP, Galyov EE: Exploitation of host cells by Burkholderia pseudomallei. Int J Med Microbiol 2004,293(7–8):549–555.PubMedCrossRef 19.

0 Turkish/Moroccan 157 3.9 (2.6–6.0) Surinamese/Antillean 233 2.5 (1.7–3.6) Refugee 79 1.8 (0.9–3.3) Age  18–24 years 143 1.0  25–44 years 886 2.4 (1.3–4.3)  45–55 years 417 5.5 (2.9–10.4)  55–64 years 369 4.7 (2.5–9.1) Women 1,016 1.6 (1.2–2.1) Educational level  High 443 1.0  Intermediate 473 1.6 (1.0–2.5)  Low 899 3.2 (2.1–4.9) Married 1,106 1.4 (1.0–1.8) Employment status  Employed >32 h/week 996 1.0  Employed <32 h/week 349 1.0 (0.7–1.5)  Unemployed Selleck Pevonedistat 194 2.6 (1.7–3.8)  Disability pension 119 14.4 (8.8–23.6)  Homemaker 157 1.1 (0.7–1.8) OR odds ratio, CI confidence interval Table 3

describes the associations with health-related quality of life, which resembles the pattern observed for a perceived poor PD0332991 molecular weight health in Table 2. Table 3 Associations between demographic factors and employment status with health related quality of life (six subscales of the SF-36) of subjects with different ethnic backgrounds Methocarbamol in a community-based Liproxstatin-1 purchase health survey in the Netherlands (n = 1,845) by multivariate linear regression analysis   General health Physical functioning Bodily pain Mental health Social functioning Vitality Intercept 81.8 (2.3) 102.4 (2.4) 100.0 (2.9) 82.9 (2.2) 97.5 (2.8)* 77.5 (2.3)* Native Dutch 0 0 0 0 0 0 Turkish/Moroccan −11.0 (1.6)* −13.1 (1.7)* −9.6 (2.0)* −8.2 (1.5)* −9.5 (2.0)* −7.3 (1.6)* Surinamese/Antillean −6.5 (1.4)* −8.2 (1.4)* −5.0 (1.7)* −3.9 (1.3)* −7.3 (1.6)* −5.5 (1.4)*

Refugee −4.5 (2.2)* −7.0 (2.3)* −6.5 (2.7)* −5.9 (2.0)* −6.6 (2.6)* −7.5 (2.1)* Age  18–24 years 0 0 0 0 0 0  25–44 years −1.7 (1.7) 1.0 (1.7) −2.2 (2.1) −0.2 (1.6) −2.4 (2.0) −3.5 (1.6)*  45–54 years −5.5 (1.8)* −4.2 (1.9)* −7.1 (2.3)* −0.3 (1.7) −3.9 (2.2) −3.0 (1.8)  55–64 years −6.6 (1.9)* −6.0 (1.9* −4.9 (2.3)* −1.6 (1.8) −2.7 (2.3) −2.5 (1.8) Women −1.4 (1.0) −2.9 (1.0)* −6.6 (1.2)* −2.8 (0.9)* −4.9 (1.2)* −4.3 (1.0)* Educational level  High 0 0 0 0 0 0  Intermediate −1.9 (1.2) −1.9 (1.3) −3.5 (1.5)* −0.5 (1.1) −1.0 (1.5) −1.3 (1.2)  Low −6.1 (1.2)* −8.7 (1.2)* −7.2 (1.5)* −4.4 (1.1)* −4.0 (1.4)* −6.1 (1.1)* Employed >32 h/week 0 0 0 0 0 0 Employed <32 h/week 0.2 (1.2) −1.1 (1.3) −0.3 (1.6) −0.1 (1.2) −1.3 (1.5) −1.1 (1.2) Unemployed −7.7 (1.5)* −4.7 (1.6)* −8.8 (1.9)* −10.5 (1.4)* −9.3 (1.8)* −7.3 (1.5)* Disability pension −28.3 (1.9)* −33.2 (2.0)* −29.3 (2.3)* −16.1 (1.8)* −31.9 (2.3)* −19.3 (1.